Phase 3
Completed N=15
The Role of Mineralocorticoid Receptors in Vascular Function
Apparent Mineralocorticoid Excess (AME)
Source: ClinicalTrials.gov NCT00759525 ↗
Enrolled (actual)
15
Serious AEs
0.0%
Results posted
May 2015
Primary outcomePrimary: Forearm Blood Flow — 1.87; 1.34 ml/100ml of tissue/min
Summary
The purpose of this study is to figure out how decreasing the activity of 11-beta hydroxysteroid dehydrogenase (11-beta HSD) will affect your blood vessel function. 11-beta HSD, which is found in the kidneys and blood vessels, is a natural protein that when active helps to keep your blood pressure under control.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Forearm Blood Flow |
1.87; 1.34 | — |
Eligibility Criteria
Inclusion Criteria
- Healthy volunteers
Exclusion Criteria
- Blood pressure above 140/90
- Abnormal physical finding
- Blood test values for total and LDL cholesterol, CBC, sodium, potassium, creatinine, and glucose laboratories greater 1.5 times normal
Data sourced from ClinicalTrials.gov (NCT00759525). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.